Kahn Brothers Group Inc. Sells 235,935 Shares of Pfizer Inc. (NYSE:PFE)

Kahn Brothers Group Inc. trimmed its stake in Pfizer Inc. (NYSE:PFE) by 23.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 761,090 shares of the biopharmaceutical company’s stock after selling 235,935 shares during the period. Pfizer makes up about 4.3% of Kahn Brothers Group Inc.’s portfolio, making the stock its 12th biggest position. Kahn Brothers Group Inc.’s holdings in Pfizer were worth $20,192,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also bought and sold shares of the company. ST Germain D J Co. Inc. boosted its stake in shares of Pfizer by 17.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 30,269 shares of the biopharmaceutical company’s stock valued at $803,000 after purchasing an additional 4,515 shares during the period. Harbor Capital Advisors Inc. boosted its holdings in shares of Pfizer by 2.5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 114,499 shares of the biopharmaceutical company’s stock valued at $3,038,000 after buying an additional 2,805 shares in the last quarter. Graypoint LLC increased its position in shares of Pfizer by 10.7% during the fourth quarter. Graypoint LLC now owns 40,528 shares of the biopharmaceutical company’s stock worth $1,075,000 after purchasing an additional 3,911 shares in the last quarter. Czech National Bank raised its stake in Pfizer by 6.4% in the fourth quarter. Czech National Bank now owns 1,228,716 shares of the biopharmaceutical company’s stock valued at $32,598,000 after buying an additional 74,350 shares during the last quarter. Finally, Fiduciary Alliance LLC grew its position in Pfizer by 15.5% during the 4th quarter. Fiduciary Alliance LLC now owns 9,803 shares of the biopharmaceutical company’s stock worth $260,000 after purchasing an additional 1,319 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the topic of a number of recent research reports. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. UBS Group increased their target price on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. Citigroup restated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Finally, Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Stock Performance

Shares of Pfizer stock opened at $22.28 on Friday. The firm has a market capitalization of $126.67 billion, a P/E ratio of 15.80, a P/E/G ratio of 0.64 and a beta of 0.58. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The firm’s 50 day moving average is $24.02 and its two-hundred day moving average is $25.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same period last year, the business earned $0.82 EPS. Pfizer’s revenue for the quarter was down 7.8% compared to the same quarter last year. Research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.72%. The ex-dividend date is Friday, May 9th. Pfizer’s dividend payout ratio is currently 124.64%.

Insider Activity

In other news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.